Animal Models of Human Infections for Evaluation of Experimental Therapies

用于评估实验疗法的人类感染动物模型

• 批准号: 8316059
• 负责人: DORISA HARRIS
• 金额: $ 8.34万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-05-01 至 2010-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8316059
• 关键词: Animal Model; Animals; Antiviral Therapy; Contracts; Disease; Dose; Drug Delivery Systems; Evaluation; Human; Immunologics; Infection; Investigational Therapies; Modeling; Monitor; Pathogenesis; Pathologic; Pharmaceutical Preparations; Process; Respiratory syncytial virus; Testing; Therapeutic Agents; Toxic effect; Virus; Virus Diseases; drug development; human disease; novel strategies

The Animal Models of Human Infections for Evaluation of Experimental Therapies contract provides one or more well-characterized virus-animal model(s) of a human viral disease for experimental use for evaluation of candidate antiviral therapies. For all models, the process of infection and/or disease pathogenesis should resemble the corresponding human disease as closely as possible. The therapeutic agents shall be evaluated for toxicity and efficacy. When appropriate, conduct immunologic, virologic, pathologic, and toxicologic tests to monitor the effects of the test agent on the infected animals, and conduct studies to evaluate novel strategies for drug delivery and dosing, including combination and sequential drug administration. These studies shall include appropriate uninfected and untreated controls.

用于评价实验疗法的人类感染动物模型合同提供了一种或多种表征良好的人类病毒性疾病病毒-动物模型，用于评价候选抗病毒疗法的实验用途。对于所有模型，感染过程和/或疾病发病机制应尽可能接近相应的人类疾病。应评价治疗剂的毒性和有效性。适当时，进行免疫学、病毒学、病理学和毒理学试验，以监测受试制剂对感染动物的影响，并进行研究，以评价药物递送和给药的新策略，包括联合给药和序贯给药。这些研究应包括适当的未感染和未治疗对照。